Giving great healthcare companies and their stories as much exposure as we can. Subscribe to our newsletter. https://xitter.cf/t.co/VE9jaNcNac

Joined September 2009
Medicus Pharma announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of the 60 patients targeted for enrollment $MDCX biotuesdays.com/2025/02/14/m…
114
Biodexa Pharmaceuticals has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA $BDRX biotuesdays.com/2025/02/10/f…
1
153
New data from BioRestorative Therapies’ ongoing Phase 2 trial of cell-based BRTX-100 in cLDD potentially show disc microenvironment remodeling in addition to reported improvements in VAS and ODI $BRTX biotuesdays.com/2025/02/10/n…
2
7
349
Tectonic Therapeutic has announced positive interim data from its Phase 1b acute hemodynamic clinical trial of TX45 in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) $TECX biotuesdays.com/2025/01/30/t…
101
IPA (ImmunoPrecise Antibodies) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and obesity $IPA biotuesdays.com/2025/01/22/i…
1
133
MeiraGTx has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD) by the FDA $MGTX biotuesdays.com/2025/01/22/f…
391